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To integrate and execute a proper preventive plan and reduce the risk of non-communicable
diseases (NCDs), policy makers need to have access to both reliable data and a unique def-
inition of metabolic syndrome (MetS). This study was conducted on the data collected by
cross-sectional studies of WHO’s STEPwise approach to surveillance of NCD risk factors
(STEPs) to estimate the national and sub-national prevalence rates of MetS in Iran in 2016.
Materials and methods
The prevalence of MetS was estimated among 18,414 individuals aged�25 years living in
urban and rural areas of Iran using various definition criteria; National Cholesterol Education
Program Adult Treatment Panel III 2004 (ATP III), International Diabetes Federation (IDF),
American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI), Joint
Interim Statement (JIS). Regional IDF (RIDF) and JIS (RJIS) were defined using ethnicity-
specific values of waist circumference for the country.
Results
National prevalence rate of MetS based on ATP III, IDF, AHA/NHLBI, JIS, RIDF and RJIS
criteria were 38.3% (95% CI 37.4–39.1), 43.5% (42.7–44.4), 40.9% (40.1–41.8), 47.6%
(46.8–48.5), 32.0% (31.2–32.9), and 40.8% (40.0–41.7), respectively. The prevalence was
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higher among females, in urban residents, and those aged 65–69 years. MetS was
expected to affect about 18.7, 21.3, 20.0, 23.3, 15.7, and 20.0 million Iranians, respectively,
based on ATP III, IDF, AHA/NHLBI, JIS, RIDF and RJIS. The two most common compo-
nents noted in this population were reduced high-density lipoprotein cholesterol (HDL-C)
levels and central obesity.
Conclusion
High prevalence rate of MetS among Iranian adults is alarming, especially among females,
urban residents, and the elderly. The JIS definition criteria is more appropriate to determine
higher number of Iranians at risk of NCDs. Proper management and prevention of MetS is
required to adopt multiple national plans including lifestyle modifications, medical interven-
tions, and public education on NCDs risk factors.
Introduction
The aging of the populations and global industrialization have resulted in an increase in the
risk of non-communicable diseases (NCDs) such as cardiovascular disease (CVD) and type 2
diabetes mellitus (T2DM). Hence, the main goal of the World Health Organization’s (WHO)
Global NCD Action Plan (25 by 25) and Sustainable Development Goal 4 (SDG4) is to reduce
NCD-related mortality by 25% and 30% in 2025 and 2030, respectively [1,2]. Metabolic syn-
drome (MetS), which is a cluster of conditions including obesity, hypertension, hypertriglycer-
idemia, low level of high-density lipoprotein cholesterol (HDL-C), and glucose intolerance,
has a positive association with the risk of CVD and T2DM [3].
Regardless of the definitions proposed for MetS [3], its prevalence is increasing in both
developed and developing countries. The prevalence of MetS in various countries is affected
by certain influential factors such as age, sex, central obesity, race, and urbanization [4]. A sig-
nificant increase in the prevalence of MetS among US adults has been reported, changing from
29.2% in the third National Health and Nutrition Examination Survey (NHANES III) in
1988–1994 to 34.2% in the NHANES 1999–2006 [5]. However, its prevalence remained stable
during 2007–2014 among US adults and the age-adjusted prevalence was reported at 34.3
±0.8% (±standard error) [6].
The reported prevalence of MetS in Middle Eastern countries varies, ranging from 16.7% to
51% [7–10]. Despite the large body of growing evidence on its regional and global prevalence,
there is a lack of reliable national data due to the scarcity of studies with good design and suffi-
cient sample size as well as lack of unique definition criteria to compare its prevalence between
countries [11]. The aim of this study was to estimate the national and sub-national prevalence
rates of MetS and its components in Iran, as a country in Middle Eastern region, using STEPs
2016 data and introducing unique MetS definition criteria with coverage of greater part of
affected Iranian populations to policymakers for reducing the risk of NCDs in a large sample
size.
Materials and methods
Study design and participants
Methodology of the study is reported in details elsewhere [12]. As summary, using a systematic
cluster random sampling frame, proportional to the adult population of each province, it was
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planned to collect data on 31,050 Iranian subjects (3,105 clusters) aged�18 years living in
urban and rural areas of 31 provinces of Iran in 2016. In addition, 10% more than estimated
sample size for each province was considered to control non-response error [12]. All Iranians
aged� 18 years who were living in Iran at the time of data collection were eligible for inclusion
in the STEPs 2016 but taking blood samples were limited to individuals who were 25 years and
above. Since most of variables/components for making MetS were taken from laboratory we
excluded participants who aged less than 25 years old in current study. Data on subjects’ his-
tory of metabolic risk factors, physical measurements, and lab assessments were collected in
three steps (Supporting information). Data on metabolic risk factors such as high fasting
plasma glucose, hypertension and hyperlipidemia were collected using self-report or medical
records (Step 1). Physical measurements included the assessment of anthropometric variables,
blood pressure, and pedometer data (Step 2). Biochemical markers such as lipid profile, and
glucose and glycated hemoglobin A1C (HbA1C) levels were measured on collected blood sam-
ples after overnight fasting (Step 3). All three of these sequential processes of data collection
were completely computer-based and digitalized. The study was approved by the Ethics Com-
mittee of the National Institute for Medical Research Development (NIMAD) under the fol-
lowing ID number: IR.NIMAD.REC.1394.032.
Data collection and measurements
In STEPs 2016, data were collected from Iranian residents who had completed a written
informed consent. Past medical history, currently used medications, and physical examination
results were also recorded. The Global Physical Activity Questionnaire (GPAQ) was used to
calculate physical activity as the Metabolic Equivalents (MET) value in minutes per week for
work, recreation, and transport domains. The WHO’s recommendation was considered to
define low physical activity as less than 600 MET minutes per week [13]. Anthropometric indi-
ces including height, weight, Body Mass Index (BMI), waist circumference (WC), hip circum-
ference (HC), and waist-to-hip-ratio (WHR) were measured as recommended by standard
protocols proposed in the STEPs manual [14]. Height was measured using a tape (0.5 cm
error) in standing position with bare foot. Weight was measured using innofit, JY-218A per-
sonal scale, SN: 14010936 (China). BMI was calculated through dividing weight (kg) by height
in squared meters (m2). The broadest area between the edge of the lower ribs and the iliac
crest was measured in order to obtain WC. Moreover, the HC was measured around the fullest
part of the buttocks at a horizontal plane while the subjects were wearing nonrestrictive under-
wear and lightweight pants or skirts [14]. Physical measurements including Systolic Blood
Pressure (SBP) and Diastolic Blood Pressure (DBP) were also measured based on the recom-
mended protocol in the STEPs manual [14]. They were measured three times using Beurer
medical, Type: BM 20, Art_Nr: 652.11 (Germany). The mean values of the second and third
readings were used for analysis.
Laboratory tests
Venous blood samples were collected after 12–14 hours of overnight fasting to measure serum
levels of fasting blood sugar (FBS), total cholesterol (TChol), HDL-C, low density lipoprotein
cholesterol (LDL-C), and triglycerides (TGs). The collected samples were stored under stan-
dard conditions (at temperatures lower than 4˚C) in vaccine transfer boxes and transferred to
the central processing/archiving laboratory of study in the Non-Communicable Diseases
Research Center (NCDRC) of Tehran University of Medical Sciences in the shortest possible
time (less than 18 hours).
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During the transfer, a digital thermometer recorded the temperature in each cold box. FBS,
TChol, and TGs levels were measured following a standard enzymatic method using an auto-
analyzer (Cobas C31, Hitachi, Japan). In patients with TGs <400 mg/dl, LDL-C levels was esti-
mated by the Friedewald formula (TChol minus HDL-C minus TGs/5 in mg/dl), whereas it
was measured directly in the others [15]. HDL-C levels were measured using the homogeneous
enzymatic cardiometric test. All the collected samples were assessed using a kit and definite
batch numbers or devices in the NCDRC laboratory.
Definitions
Table 1 presents details on the six criteria used to define MetS: the National Cholesterol Educa-
tion Program Adult Treatment Panel III (ATP III), the International Diabetes Federation
(IDF), the American Heart Association/National Heart, Lung, and Blood Institute (AHA/
NHLBI), and the Joint Interim Statement (JIS) [3,16–18]. According to the recommendations
of the Iranian National Committee of Obesity, the ethnicity-specific values were applied in the
IDF and JIS definitions [19]. In this regard, the Iranian cutoffs for WC were introduced as
Regional IDF (RIDF) and Regional JIS (RJIS), respectively.
Data analysis
In this study, the data of 18,414 individuals aged�25 years old who participated in all the
three steps and had reliable results based on the STEPs protocol and no missings in the items
relevant to the MetS defintitions were used [14]. Applying complex survey weights, as
described previously [12], the estimated prevalence rates standardized for sex, area of resi-
dence, and age subgroups (25–34, 35–44, 45–54, 55–64, 65–69, 70+) were reported for national
and sub–national levels with 95% confidence intervals (95% CI). The burden of population
was calculated as the number of people from each gender and residency area who have MetS
based on each definition criteria.
Table 1. Diagnostic criteria used to define MetS.
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ATP III: National Cholesterol Education Program Adult Treatment Panel III; IDF: International Diabetes Federation; AHA/NHLBI: American Heart Association/
National Heart, Lung, and Blood Institute; JIS: Joint Interim Statement; FBS: Fasting Blood Sugar; WC: Waist circumference; TGs: Triglycerides; HDL-C: High Density
Lipoprotein Cholesterol; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; MetS: Metabolic Syndrome.
https://doi.org/10.1371/journal.pone.0241926.t001
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The statistical analyses were performed using STATA version 12 and R statistical packages
version 3.4.0. P-value� 0.05 was set as statistically significant. Age-standardization of sub-
national results was performed based on the National Population and Housing Census con-
ducted by the Statistical Center of Iran in 2016 [20]. The level of agreement between different
definitions of MetS, ranging from −1 to +1, was calculated through the Cohen’s Kappa statistic.
A value of 1 indicated perfect agreement, while a value of 0 represented that the agreement was
the result of no better than chance [21].
Results
The study was conducted on 18,414 participants including 8,570 males and 9,844 females aged
between 25 and 70+ years (mean age: 47.4, 95% CI: 47.2–47.6). Table 2 presents the overall
and sex-based demographic and biochemical characteristics of the included subjects.
The estimated overall prevalence of MetS for all age groups, irrespective of sex or area of
residence, was 32.0–47.6% using various criteria. The highest rate (47.6%) was estimated based
on JIS (Table 3). The estimated national burden of MetS for all ages was 7.6–10.5 and 7.1–12.7
million persons among males and females, respectively. The rate was about 11.7–18.4 and 3.0–
4.9 million persons in urban and rural residents, correspondingly (Table 3). The national prev-
alence rate was higher among older age groups, with the highest spike reported in the 65–69
age group regardless of the definition criteria (Fig 1).
The highest prevalence rate of MetS were estimated in uneducated subjects (61.5%) and
those with low physical activity (51.8%) (Table 4). Based on all criteria, the most common
components of MetS reduced in this population were low HDL-C levels (<40 mg/dl in males
and<50 mg/dl in females) and the obesity domain, at 69.3–71.1%, and 44.1–66.9%, respec-
tively (Table 5).
The proportion of the highest and the lowest sub-national age-standardized prevalence
rates of MetS estimated by JIS and RIDF were 48.2% and 19.2%, respectively. As for ATP III,
IDF, AHA/NHLBI, JIS, RIDF and RJIS, the rates are as high as 87%, 43%, 66%, 40%, 79%, and
60%, correspondingly. In line with the national prevalence rate of MetS (data available at
https://vizit.report/en/index.html), the prevalence rate in most provinces was highest in the
65–69 age group.
The age-standardized sub-national prevalence based on most of the used criteria (except for
RIDF and RJIS) was higher among females in nearly all the provinces (Fig 2). According to the
ATP III, IDF, AHA/NHLBI, and JIS definitions, there rates were higher in all the provinces
among females and in urban populations (Figs 3–6). On the other hand, the rates based on RIDF
and RJIS, presented in Figs 7 and 8, were shown to be higher among males and in urban residents.
The kappa agreement values between different definition criteria are presented in S1 Table.
The lowest consistency (15.6%) was noted between the subjects determined to have MetS by
the JIS criteria, but not the RIDF criteria (Table 6).
Sex pattern of the highest inconsistency was shown between those with MetS diagnosed by
JIS but not by RIDF (20.9%) or ATP III (10.6%), in females and males, respectively.
However, similar low inconsistency rate were observed between females diagnosed by ATP
III, but not by IDF (1.1%), and males diagnosed by IDF or JIS, but not by RJIS (1.0%). Com-
pared with RIDF, RJIS was reported to be capable of diagnosing more Iranians with MetS
(9.1% in females, and 8.4% in males) (Table 6).
Discussion
This nationwide study was conducted to estimate the prevalence rate of MetS in Iran. The
results revealed that the national burden and the prevalence of MetS are alarming, particularly
PLOS ONE Nationwide MetS prevalence
PLOS ONE | https://doi.org/10.1371/journal.pone.0241926 March 3, 2021 5 / 20
among females, in urban populations, and the 65–69 age group. The highest prevalence rate
was observed using the JIS criteria. The two most common components of MetS reported in
this population were increased WC and reduced HDL-C.
In our study, the prevalence rate of MetS was considerably higher than that reported in
most Middle Eastern countries and even other parts of the world. The prevalence of MetS for
all ages is reported to be about 21.3% in China, 27.8% in Spain, and 34.3% in the US [6,22,23].
The overall prevalence of MetS in the Middle Eastern countries is reported to range from
16.7% and 18.9% in Saudi Arabia [7] to 26.5% and 33.7% in Qatar, based on ATP III and IDF
criteria respectively [24]. The prevalence of MetS in 2013 was 31.3% by ATP III, 35.0% by IDF,
35.8% by AHA/NHLBI, and 41.8% by JIS criteria in the biggest city of Iran (Tehran) [25].
Table 2. Socio-demographic, lifestyle and clinical characteristics of the participants.
Variable Total (95% CI) Males (95% CI) Females (95% CI) P-value
Mean Age (yr) 47.4 (47.2–47.6) 48.0 (47.6–48.3) 47.0 (46.7–47.3) <0.001
Years of education (%)
Illiterate 18.2 (17.6–18.8) 12.3 (11.6–13.0) 23.4 (22.5–24.2) <0.001
Primary 29.1 (28.4–29.8) 28.1 (27.1–29.0) 30.0 (29.1–31.0) <0.001
7–12 years 36.7 (35.9–37.4) 41.5 (40.4–42.6) 32.4 (31.5–33.4) 0.004
Academic 16.0 (15.5–16.6) 18.1 (17.3–19.0) 14.2 (13.5–14.9) <0.001
Job (%)
Employed 38.8 (38.1–39.6) 73.4 (72.4–74.3) 8.7 (8.1–9.3) <0.001
Housewife 46.1 (45.4–46.9) 1.0 (0.8–1.2) 85.5 (84.8–86.2) <0.001
Unemployed 15.0 (14.5–15.6) 25.6 (24.7–26.6) 5.8 (5.3–6.3) <0.001
Marital Status (%)
Divorced 1.8 (1.6–2.0) 0.7 (0.5–0.9) 2.8 (2.5–3.1) <0.001
Married 83.2 (82.6–83.8) 89.9 (89.2–90.5) 77.4 (76.5–78.2) <0.001
Never married 8.0 (7.5–8.4) 8.2 (7.6–8.8) 7.7 (7.2–8.3) 0.278
Widowed 7.0 (6.6–7.4) 1.2 (1.0–1.5) 12.1 (11.4–12.7) <0.001
Self-reported medication for (%)
Diabetes 13.5 (12.7–14.2) 10.0 (9.1–10.9) 17.5 (16.3–18.7) <0.001
Hypertension 67.6 (66.0–69.2) 64.4 (61.7–67.0) 69.6 (67.6–71.7) 0.002
Dyslipidemia 31.3 (30.6–32.0) 33.7 (32.7–34.8) 29.2 (28.3–30.2) <0.001
Low Physical activity (<600 METs) (%) 55.7 (54.9–56.5) 47.2 (46.0–48.4) 62.0 (61.0–63.0) <0.001
WC (cm) 92.2 (92.0–92.4) 92.2 (91.9–92.5) 92.1 (91.8–92.4) 0.552
WHR (�100) 90.7 (90.5–90.8) 93.0 (92.8–93.2) 88.6 (88.4–88.8) <0.001
Weight (kg) 71.9 (71.7–72.2) 75.4 (75.1–75.7) 68.9 (68.6–69.2) <0.001
BMI (kg/m2) 27.0 (26.9–27.1) 25.9 (25.8–26.0) 28.0 (27.9–28.1) <0.001
SBP (mmHg) 126.9 (126.7–127.2) 127.1 (126.7–127.5) 126.8 (126.3–127.2) 0.200
DBP (mmHg) 77.8 (77.6–77.9) 78.4 (78.2–78.6) 77.2 (77.0–77.5) <0.001
FBS (mg/dl) 99.1 (98.5–99.8) 98.7 (97.7–99.6) 99.5 (98.7–100.4) 0.194
TChol (mg/dl) 164.6 (164.0–165.2) 161.1 (160.2–162.0) 167.5 (166.7–168.3) <0.001
TGs (mg/dl) 129.0 (127.6–130.4) 136.8 (134.7–138.8) 122.4 (120.5–124.3) <0.001
LDL-C (mg/dl) 97.7 (97.2–98.3) 96.1 (95.3–96.8) 99.2 (98.4–99.9) <0.001
HDL-C (mg/dl) 41.2 (41.0–41.4) 37.9 (37.6–38.1) 44.0 (43.7–44.2) <0.001
WC: Waist circumference; WHR: Waist Hip Ratio; BMI: Body Mass Index; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; FBS: Fasting Blood Sugar;
TChol: Total Cholesterol; TGs: Triglycerides; LDL-C: Low Density Lipoprotein Cholesterol; HDL-C: High Density Lipoprotein Cholesterol.
-Data are presented as point estimates and 95% CI.
-P� 0.05 was considered as statistically significant by survey logistic or linear regression models.
https://doi.org/10.1371/journal.pone.0241926.t002
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Perhaps, one of the likely reasons for the observed variations between countries could be
attributed to the cutoff points used to define central obesity. In addition, WC, which is consid-
ered as the core component in defining MetS using the IDF criteria, is influenced by ethnicity-
specific values. However, the optimal WC cut off points recommended by the National Com-
mittee of Obesity (�95 cm for Iranians regardless of gender) [19] are higher than that sug-
gested by the Europid for females and lower for males. This may result in a higher prevalence
rate of MetS among males.
The growing trend in the prevalence rate of MetS by age in our study is in line with the first
nationwide survey conducted in the same population [26]. On the other hand, in the latter
study the majority of the affected individuals belonged to the 55–64 age group, our current
results are consistent with the findings of our neighboring country i.e. Turkey [27].
Due to the remarkable aging of the Iranian population in recent years and an increase in
life expectancy, a rise in the prevalence of MetS among the elderly was expected. In addition,
the increase in the number of post-menopausal women due to aging can also be associated
with the accumulation of excess abdominal fat and the surging trend noted among females
[28]. In proportion to the increase reported in MetS rates, the prevalence of other NCDs risk
factors such as diabetes and obesity has also increased in not only our country but also the
region [29,30].
Fig 1. Age trends of MetS among the Iranian population based on sex and area of residence.
https://doi.org/10.1371/journal.pone.0241926.g001
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Fig 2. Gender and geographical distribution of sub-national prevalence of MetS based on six different definitions (age-standardized).
https://doi.org/10.1371/journal.pone.0241926.g002
Fig 3. Geographical distribution of the prevalence of MetS by ATP III 2004.
https://doi.org/10.1371/journal.pone.0241926.g003
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Fig 4. Geographical distribution of the prevalence of MetS by IDF.
https://doi.org/10.1371/journal.pone.0241926.g004
Fig 5. Geographical distribution of the prevalence of MetS by AHA/NHLBI.
https://doi.org/10.1371/journal.pone.0241926.g005
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Fig 6. Geographical distribution of the prevalence of MetS by JIS.
https://doi.org/10.1371/journal.pone.0241926.g006
Fig 7. Geographical distribution of the prevalence of MetS by Regional IDF.
https://doi.org/10.1371/journal.pone.0241926.g007
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The gender pattern of the national and sub-national MetS prevalence rates of all ages
among our studied subjects was inconsistent with that of studies conducted in other Middle
Eastern or non-Middle Eastern countries using similar definition criteria [8,31,32]. This gen-
der disparity might be attributed to multiparity, low levels of HDL-C, and sedentary lifestyle
among females, as opposed to males.
In corroboration with the findings of two systematic reviews on the prevalence of MetS in
the Middle East countries and Asia-pacific region, a higher prevalence rate was noted in the
urban population of this study [33,34]. Furthermore, an association between MetS prevalence
and education level was observed. As opposed to lower education levels, higher education lev-
els appeared to be correlated with lower engagement in harmful habits such as unhealthy eat-
ing habits, sedentary lifestyle, smoking, and low access to healthcare services [35]. Overall,
socio-environmental factors such as rapid population growth, migration from rural to urban
areas, and unhealthy lifestyles were recognized as some of the factors associated with the
increased risk of MetS and its components [36].
The most common components of MetS in our study were similar to those from other
countries in the region [37]. The reported prevalence of dyslipidemia in Iran was about 43.9%
[38], which was higher than the values reported in Turkey (31.8%) and lower than those
reported in the Arab populations e.g. Jordan (62.7%) [37]. These reports were comparable to
the ones reported from non-Middle Eastern countries such as the US (35.0% of males and
40.4% of females) in a survey of 5455 adults conducted in the 2013–2014 NHANES survey
[39].
The reason behind these variations might be ascribed to an ethnic predisposition to insulin
resistance coupled with the high-caloric unhealthy diets in Iran similar to other Middle East-
ern countries [40,41]. However, the similarity in gender differences could be partly related to
the sedentary lifestyle that is more prevalent among females than in males. Creer et al.
Fig 8. Geographical distribution of the prevalence of MetS by Regional JIS.
https://doi.org/10.1371/journal.pone.0241926.g008
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conducted a longitudinal study and found significant effects of physical inactivity, sedentary
behavior, and cardiorespiratory fitness (CRF) on the development of MetS [42]. A rise in the
rate of physical inactivity, from 15.5% in 2007 to 21.5% in 2011, was reported in a study from
Iran [43]. Another reason of these findings may be attributed to rapid aging of the Iranian pop-
ulation that has resulted in a nearly four times increase in their mean age over the past 60 years
[44].
Like many studies, our study has its strengths and limitations. The main strength of our sur-
vey was the assessment of the prevalence rate of MetS in a large population-based sample of
both sexes and across a broad age spectrum, in urban and rural areas of all provinces of Iran.
Furthermore, our results present the sub-national age-standardized prevalence rate, which has
been reported by a few studies so far. Moreover, it provides the possibility to compare different
provinces in terms of sex and age patterns of MetS prevalence. Therefore, policymakers can
utilize the results to integrate appropriate preventive programs. The third strength is the com-
parison of prevalence rates by the use of various definition criteria and estimation of preva-
lence rates of MetS’ components based on data analysis in a unique lab center (NCDRC)
which improves the accuracy of the results.
The main limitation of this study is its cross-sectional nature. Future studies are required to
offer different insights into MetS.
Conclusion
In conclusion, our findings indicate an alarming prevalence of MetS, both at national and sub-
national levels, particularly among females, in the urban population, and the elderly. The
Table 6. Inconsistency (%) between different definitions of MetS.
Sex MetS definition ATP III- IDF- AHA/NHLBI- JIS- Regional IDF- Regional JIS-
Both ATP III+ 3.6 (3.3–4.0) 0 0 11.2 (10.7–11.8) 3.3 (3.0–3.7)
IDF+ 8.9 (8.4–9.4) 6.7 (6.3–7.2) 0 11.5 (10.9–12.0) 6.8 (6.4–7.3)
AHA/NHLBI+ 2.6 (2.3–2.9) 4.1 (3.8–4.5) 0 12.3 (11.8–12.9) 3.6 (3.2–3.9)
JIS+ 9.4 (8.8–9.9) 4.1 (3.8–4.5) 6.7 (6.3–7.2) 15.6 (15.0–16.2) 6.8 (6.4–7.3)
Regional IDF+ 5.0 (4.6–5.4) 0 3.5 (3.2–3.8) 0 0
Regional JIS+ 5.8 (5.4–6.3) 4.1 (3.8–4.5) 3.5 (3.2–3.8) 0 8.8 (8.3–9.3)
Female ATP III+ 1.1 (0.9–1.3) 0 0 14.2 (13.4–15.1) 6.1 (5.5–6.7)
IDF+ 7.9 (7.2–8.6) 5.2 (4.7–5.7) 0 19.4 (18.4–20.3) 11.8 (11.0–12.6)
AHA/NHLBI+ 3.1 (2.6–3.6) 1.5 (1.2–1.8) 0 15.7 (14.8–16.6) 6.6 (6.0–7.2)
JIS+ 8.3 (7.6–9.0) 1.5 (1.2–1.8) 5.2 (4.7–5.7) 20.9 (19.9–21.9) 11.8 (11.0–12.6)
Regional IDF+ 1.6 (1.3–1.9) 0 0 0 0
Regional JIS+ 2.6 (2.2–3.1) 1.5 (1.2–1.8) 0 0 9.1 (8.4–9.8)
Male ATP III+ 6.6 (6.0–7.3) 0 0 7.7 (7.0–8.4) 0
IDF+ 10.0 (9.2–10.8) 8.6 (7.8–9.3) 0 2.1 (1.7–2.5) 1.0 (0.7–1.3)
AHA/NHLBI+ 2.1 (1.7–2.5) 7.2 (6.6–7.9) 0 8.4 (7.7–9.1) 0
JIS+ 10.6 (9.8–11.4) 7.2 (6.6–7.9) 8.6 (7.8–9.3) 9.4 (8.6–10.1) 1.0 (0.7–1.3)
Regional IDF+ 8.9 (8.2–9.7) 0 7.6 (6.9–8.2) 0 0
Regional JIS+ 9.6 (8.9–10.4) 7.2 (6.6–7.9) 7.6 (6.9–8.2) 0 8.4 (7.7–9.1)
ATP III: National Cholesterol Education Program Adult Treatment Panel III; IDF: International Diabetes
Federation; AHA/NHLBI: American Heart Association/National Heart, Lung, and Blood Institute; JIS: Joint Interim
Statement.
-Data are presented as point estimates (%) and 95% CI.
https://doi.org/10.1371/journal.pone.0241926.t006
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highest prevalence rate observed using the JIS criteria. This could be indicated to this fact that
the JIS criteria is more appropriate for our country due to its high coverage of population at
risk of NCDs. The management and prevention of MetS requires multiple actions through sev-
eral modalities, including raising public awareness on NCDs risk factors, lifestyle modifica-
tions, and pharmacological interventions to modify risk factors such as lipid abnormalities.
Furthermore, a unique universal criterion with ethnicity-specific values for waist circumfer-
ence is needed for the identification of MetS and more accurate comparison of its prevalence
rates in different countries.
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